Article Text

Download PDFPDF
67 Breast biopsy patterns and findings among older women undergoing screening mammography: what is the impact of age and comorbidity?
  1. Dejana Braithwaite1,
  2. Shailesh Advani1,
  3. Linn Abraham2,
  4. Diana Buist2,
  5. Ellen O’Meara2,
  6. Diana Miglioretti3,2,
  7. Brian Sprague4,
  8. Louise Henderson5,
  9. Tracy Onega6,
  10. John Schousboe7,
  11. Dongyu Zhang1,
  12. Joshua Demb8,
  13. Louise Walter9,
  14. Karla Kerlikowske8,9
  1. 1Department of Oncology, Georgetown University Medical Center, Washington, USA
  2. 2Kaiser Permanente Washington Health Research Institute, Seattle, USA
  3. 3Department of Public Health Sciences, School of Medicine, University of California, Davis, Davis, USA
  4. 4Department of Surgery, University of Vermont College of Medicine, Burlington, USA
  5. 5Department of Radiology, University of North Carolina at Chapel Hill, Chapel Hill, USA
  6. 6Department of Biomedical Data Science, Geisel School of Medicine at Dartmouth, Lebanon, USA
  7. 7Park Nicollet Clinic and Health Partners Institute, Bloomington, USA
  8. 8Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, USA
  9. 9Department of Medicine, University of California, San Francisco, San Francisco, USA


Purpose Biopsy use and findings following screening mammography among older women are not well established.

Method We included 171,636 women ages 66–99 years with at least one screening mammogram from the Medicare-linked Breast Cancer Surveillance Consortium (BCSC, 1999–2010). We calculated percentage of screens followed by biopsy within 90 days by age and comorbidity.

Results Among 527,254 screening mammograms, 6587(1.2%) were followed by biopsy within 90 days. Whereas proportions of screens followed by any biopsy did not vary significantly by age groups (ages 66–74:1.3%, ages 75–84: 1.2%, ages 85–99:1.2%, p trend=0.07), they increased with increasing Charlson Comorbidity score (CCS) ([ages 66–74: CCS0:1.2%, CCS1: 1.3%, CCS≥2:1.6%; p trend=<0.001]; [ages 75–84:CCS0: 1.2%, CCS1:1.3%, CCS≥2:1.3%; p trend=0.01]; [ages 85–99: CCS0:1.1%, CCS1:1.2%, CCS≥2:1.4%; p trend=0.16]). Further, proportions of benign biopsy increased with increasing CCS across all age groups (ages 66–74: CCS0:0.77%, CCS1:0.88%, CCS≥2:0.94%, p trend<0.001; ages 75–84: CCS0:0.62%, CCS1:0.75%, CCS≥2:0.78%, p trend=0.001 and ages 85–99: CCS0:0.48%, CCS1:0.57% and CCS≥2:0.61%, p trend=0.23). Proportions of any biopsy with a result of invasive cancer did not vary significantly by CCS across all age groups ([ages 66–74: CCS0:28.4%, CCS1:25.5%, CCS≥2:30.8%; p trend=0.93]; [ages 75–84: CCS0:37.2%, CCS1:36.0%, CCS≥2:32.0%; p trend=0.15]; [ages 85–99: CCS0:46.8%, CCS1:43.5%, CCS≥2:43.8%; p trend=0.60]).

Conclusions Whereas proportions of screening mammograms followed by biopsy did not differ significantly by age group, proportions increased with increasing comorbidity, overall and within age groups, resulting in lower invasive cancer yield for the oldest age groups. Proportions of benign biopsy also increased with increasing comorbidity. These results highlight that older women with significant comorbidity may be harmed by downstream procedures following screening mammography.

Acknowledgements This study was supported by the U.S. National Cancer Institute 1R01CA207361-01A1 grant (to Dr. D. Braithwaite) and BCSC P01CA154292 grant. We thank all study participants and BCSC staff.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.